- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07932275
Long-term Complications in Patients With Previous Endoscopic Papillary Large Balloon Dilation: a Nationwide Retrospective Study
Endoscopic retrograde cholangiopancreatography (ERCP) using standard techniques successfully removes common bile duct stones in most cases, but in 10-15% of patients, complex stone features or challenging biliary anatomy require advanced methods such as Endoscopic Papillary Large Balloon Dilation (EPLBD). Although EPLBD effectively facilitates the removal of difficult stones, it disrupts the papillary orifice and removes the natural barrier between the duodenum and the biliary tract, potentially increasing the risk of bacterial translocation and ascending cholangitis. This study aims to evaluate the long-term outcomes (over one year) in patients undergoing EPLBD, focusing primarily on the incidence of post-procedure cholangitis and secondarily on the rate of recurrent choledocholithiasis.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Common bile duct stones are still the most common indication for endoscopic retrograde cholangiopancreatogrphy (ERCP). In the majority of cases bile duct clearance is obtained with standard techniques such as the execution of endoscopic sphincterotomy and the use of baskets and balloon catheters for bile duct stones extraction. In up to 10-15% of the cases, conventional techniques are unsuccessful defining the condition of difficult bile duct stones. The reason for a failed bile stones extraction is usually related to specific stone characteristics such as size, number, shape, consistency, location of the stone or certain biliary anatomy (biliary variants, altered anatomy intrahepatic locations of the stones, impacted stone). In these situations, the standard ERCP techniques for stones extraction could not be sufficient and advanced techniques are needed in order to obtain bile duct clearance. These includes endoscopic papillary large balloon dilation (EPLBD), mechanical lithotripsy and/or cholangioscopic-assisted lithotripsy. EPLBD is performed with a balloon catheter at the level of the papilla Balloon dilation allows a controlled dilation of the papilla and a subsequent extraction of the stones with the standard extraction devices. It demonstrated in different studies a high efficacy for difficult bile duct extraction compared to endoscopic sphincterotomy alone. EPLBD cause a complete disruption of the papilla orifice with a significant open communication between the duodenal lumen and the biliary tract. The absence of an anatomical barrier between the bile tract and the duodenal lumen could cause the translocation of intestinal bacteria and/or contamination with food particles with the potential risk of ascending cholangitis.
Aim of our study is to evaluate the natural history of patients who underwent to EPLBD especially focused on the appearance of cholangitis and bile duct stones relapse during a long-term follow-up (> 1 year). The primary objective is to evaluate the incidence of cholangitis episodes after EPLBD during a follow-up period of at least of 1 year. The secondary objective is to evaluate choledocholithiasis recurrence during a follow-up period of at least 1 year.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Andrea Anderloni, MD
- Numéro de téléphone: +39 0382503370
- E-mail: a.anderloni@smatteo.pv.it
Lieux d'étude
-
-
Pavia
-
Pavia, Pavia, Italie, 27100
- Recrutement
- Fondazione IRCCS Policlinico San Matteo di Pavia
-
Contact:
- Andrea Anderloni, MD
- Numéro de téléphone: 0382503370
- E-mail: a.anderloni@smatteo.pv.it
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with an indication for ERCP for difficult bile stones in 15% of cases and application of EPLBD in 80% of cases.
La description
Inclusion Criteria:
- All patients with a diagnosis of choledocholithiasis who underwent ERCP with EPLBD from January 2014 to March 2023 with complete bile duct stone clearance in one or multiple ERCP sessions will be included in the study.
Exclusion Criteria:
- Patients with age less than 18 years old or with surgically altered anatomy or with orthotopic liver transplantation will be excluded from the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: RETROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of cholangitis
Délai: 12 months
|
evaluate the incidence of cholangitis episodes after EPLBD during a follow-up period of at least of 1 year. |
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of ERCP
Délai: 12 months
|
1-year cumulative incidence of ERCP performed for bile duct stones relapse. |
12 months
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Wide
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .